Matthew D Hellmann
Overview
Explore the profile of Matthew D Hellmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
41759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Elkrief A, Alessi J, Ricciuti B, Brown S, Rizvi H, Preeshagul I, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37487667
Background: Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have...
12.
Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, et al.
Clin Cancer Res
. 2023 Jul;
29(21):4408-4418.
PMID: 37432985
Purpose: We sought to identify features of patients with advanced non-small cell lung cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors (ICI), and how these might differ...
13.
Gutierrez M, Lam W, Hellmann M, Gubens M, Aggarwal C, Tan D, et al.
Nat Med
. 2023 Jul;
29(7):1718-1727.
PMID: 37429923
Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC), only a subset of patients will respond due to a heterogenous tumor microenvironment. KEYNOTE-495/KeyImPaCT is an ongoing biomarker-directed, adaptively...
14.
Rudin C, Balli D, Lai W, Richards A, Nguyen E, Egger J, et al.
J Thorac Oncol
. 2023 May;
18(9):1222-1232.
PMID: 37210008
Introduction: A small percentage of patients with SCLC experience durable responses to immune checkpoint blockade (ICB). Defining determinants of immune response may nominate strategies to broaden the efficacy of immunotherapy...
15.
Ravi A, Hellmann M, Arniella M, Holton M, Freeman S, Naranbhai V, et al.
Nat Genet
. 2023 Apr;
55(5):807-819.
PMID: 37024582
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we...
16.
Pai J, Hellmann M, Sauter J, Mattar M, Rizvi H, Woo H, et al.
Cancer Cell
. 2023 Mar;
41(4):776-790.e7.
PMID: 37001526
Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq analysis of 187,650 T ...
17.
Rizvi N, Ademuyiwa F, Cao Z, Chen H, Ferris R, Goldberg S, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36918220
Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or...
18.
Dercle L, Fronheiser M, Rizvi N, Hellmann M, Maier S, Hayes W, et al.
J Thorac Oncol
. 2023 Jan;
18(5):587-598.
PMID: 36646209
Introduction: We aimed to define a baseline radiomic signature associated with overall survival (OS) using baseline computed tomography (CT) images obtained from patients with NSCLC treated with nivolumab or chemotherapy....
19.
Chow A, Uddin F, Liu M, Dobrin A, Nabet B, Mangarin L, et al.
Immunity
. 2022 Dec;
56(1):93-106.e6.
PMID: 36574773
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8 T cells. Here, we comprehensively profiled CD39 expression in...
20.
Zatzman M, Fuligni F, Ripsman R, Suwal T, Comitani F, Edward L, et al.
Sci Adv
. 2022 Nov;
8(47):eabn0238.
PMID: 36417526
Cancers are often defined by the dysregulation of specific transcriptional programs; however, the importance of global transcriptional changes is less understood. Hypertranscription is the genome-wide increase in RNA output. Hypertranscription's...